Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology
in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis …

Controversy persists regarding the role of histopathology in the distinction between essential
thrombocythemia (ET) and early-prefibrotic primary myelofi-brosis (PMF) presenting with …

We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between
1967 and 2023: median age 58 years (18–90), females 63%, JAK2/CALR/MPL-mutated …

The role of histopathology in the diagnosis of essential thrombocythemia (ET) is
controversial, and there has been little attempt to quantitate interobserver variability …

Purpose Established risk factors for thrombosis in essential thrombocythemia (ET) include
age and previous vascular events. We aimed to refine this risk stratification by adding …

Essential thrombocythemia (ET) is currently diagnosed either by the British Committee of
Standards in Haematology (BCSH) criteria that are predominantly based on exclusion and …

The current retrospective study involving a total of 1607 patients was designed to identify
clinical and molecular variables that were predictive of inferior myelofibrosis‐free survival …

Unlike the case with thrombosis, prognostic models for survival and leukemic transformation
(LT) in essential thrombocythemia (ET) are not available. Among 605 patients with ET seen …

Brousseau M, Parot‐Schinkel E, Moles M‐P, Boyer F, Hunault M & Rousselet M‐C (2010)
Histopathology56, 758‐767 Practical application and clinical impact of the WHO …

Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health
Organization (WHO) classification. We developed a prognostic model to predict survival at …